

## AcpA Is a *Francisella* Acid Phosphatase That Affects Intramacrophage Survival and Virulence<sup>∇</sup>

Nrusingh P. Mohapatra, Ashwin Balagopal, Shilpa Soni, Larry S. Schlesinger, and John S. Gunn\*

Center for Microbial Interface Biology, Department of Molecular Virology, Immunology, and Medical Genetics, and Department of Internal Medicine, Division of Infectious Diseases, The Ohio State University, Columbus, Ohio 43210

Received 2 August 2006/Returned for modification 20 September 2006/Accepted 12 October 2006

**AcpA of *Francisella* spp. is a respiratory-burst-inhibiting acid phosphatase that also exhibits phospholipase C activity. To better understand the molecular basis of AcpA in virulence, a deletion of *acpA* was constructed in *Francisella novicida*. The phosphatase and lipase activities were reduced 10-fold and 8-fold, respectively, in the *acpA* mutant compared to the wild type and were found mostly associated with the outer membrane. The *acpA* mutant was more susceptible to intracellular killing than the wild-type strain in the THP-1 human macrophage-like cell line. In addition, mice infected with the *acpA* mutant survived longer than the wild-type strain and were less fit than the wild-type strain in competition infection assays. Transmission electron microscopy showed that the *acpA* mutant was delayed in escape from macrophage phagosomes, as more than 75% of *acpA* mutant bacteria could still be found inside phagosomes after 12 h of infection in THP-1 cells and human monocyte-derived macrophages, whereas most of the wild-type bacteria had escaped from the phagosome by 6 h postinfection. Thus, AcpA affects intracellular trafficking and the fate of *Francisella* within host macrophages.**

*Francisella tularensis* is a gram-negative, facultative intracellular pathogen that causes tularemia in humans and other mammals including rodents (38). The two primary human pathogens are *F. tularensis* subsp. *tularensis* (type A strain) and *F. tularensis* subsp. *holarctica* (type B strain). The type A strain is found predominantly in North America, is highly infectious, and causes a life-threatening disease in humans, especially when inhaled (10). Type B strains are found primarily in Europe and are considered to be less virulent for mammals than the type A strain (10). An attenuated live vaccine strain (LVS) was derived from a type B strain (12), and it elicits a protective response in humans, monkeys, guinea pigs and mice against systemic challenge with virulent type A *F. tularensis* (9, 12, 13, 18, 35, 36). *Francisella novicida*, a close relative of type A *F. tularensis*, is a much less frequent cause of infection in humans than either type A or type B (19). Nevertheless, *F. novicida*, *F. tularensis* subsp. *tularensis*, and *F. tularensis* subsp. *holarctica* all cause a lethal systemic infection in mice when inoculated by most routes (19).

The virulence mechanisms of this bacterium are not clear, although the products of several genes such as *mglA* and the pathogenicity island genes *iglC*, *iglD*, and *pdpA-D* that help *Francisella* to survive inside macrophages have been identified (6, 15, 17). However, the exact functions of these genes are not known. MglA shares homology with the SspA of *Escherichia coli*, which regulates stationary-phase gene transcription by interacting with RNA polymerase (40). MglA regulates several virulence factors within the pathogenicity island, including *iglC* (25), which is important for the ability of *Francisella* spp. to

escape from the phagosome. Several studies have shown that *F. tularensis* resides inside a membrane-bound phagosome during its initial growth in a macrophage and that it is released into the cytoplasm during a later phase of growth (2, 11, 16).

Acid phosphatases are ubiquitous in nature and are present in almost all bacteria. These enzymes have been identified and characterized for many eukaryotes and prokaryotes and are divided into subgroups according to their substrate specificities, molecular weights, and sensitivities to known inhibitors (30). Acid phosphatases catalyze the hydrolysis of phosphomonoesters at an acidic pH. In several species, they have been implicated as virulence factors and help the bacteria to survive inside phagocytes (4, 7, 14, 23, 27, 28, 31), often by inhibiting the respiratory burst (4, 20, 23, 29, 31).

The published genome sequence of *F. tularensis* Schu 4 revealed the presence of four acid phosphatases (*acpA* [FTT0221], *acpB* [FTT0156], *acpC* [FTT0620], and *hap* [FTT1662c] [a pseudogene in Schu 4 but not LVS]) (21). AcpA (57 kDa) is a polyspecific periplasmic acid phosphatase that is highly expressed by *F. tularensis* (7, 27) and shows no significant global amino acid sequence similarity with any protein in the Protein Data Bank (8). This protein is also unusual in that it exhibits phospholipase C activity (27). Previous studies reported that *Francisella* AcpA has respiratory-burst-inhibiting properties and broad substrate specificity (27). It has also been shown that a transposon insertion in the 3' region of the *acpA* open reading frame did not result in an intramacrophage survival defect or a loss of virulence (7). In the present study, we constructed a deletion of the entire *acpA* gene in *F. novicida* and analyzed its role in intracellular trafficking in macrophages and virulence in mice.

### MATERIALS AND METHODS

#### Bacterial strains, plasmid construction, and molecular biology techniques.

Bacterial strains, plasmids, and primers used in this study are listed in Tables 1 and 2. *F. novicida* U112 was routinely grown at 37°C on cysteine heart agar

\* Corresponding author. Mailing address: The Ohio State University, Tzagournis Medical Research Facility, 420 W. 12th Ave., Columbus, OH 43210-1214. Phone: (614) 292-6036. Fax: (614) 292-5495. E-mail: gunn.43@osu.edu.

<sup>∇</sup> Published ahead of print on 23 October 2006.

TABLE 1. Strains and plasmids

Strain or plasmid	Genotype or relevant phenotype	Source or reference
<b>Strains</b>		
<i>Francisella</i>		
JSG1819	<i>Francisella novicida</i> U112	ATCC
JSG2660	JSG1819 with $\Delta acpA::kan$	This work
JSG2661	JSG2660 complemented with <i>acpA</i> carried on pKK214groEL	This work
<i>E. coli</i>		
DH5 $\alpha$	F <sup>-</sup> 80dlacZ $\Delta$ M15 $\Delta$ (lacZYA-argF)U169 endA1 recA1 hsdR17 deoR thi-1 supE441 gyrA96 relA1	BRL
<b>Plasmids</b>		
pUC18	High-copy cloning vector	NEB
pKK214	Low-copy expression vector with GroEL promoter of <i>F. tularensis</i> LVS	39
pAcpUp	pUC18- <i>acpA</i> upstream region	This work
pAcpUpDn	pUC18- <i>acpA</i> upstream and downstream region	This work
pAcpA-Kan	pAcpUpDN with Kan cassette	This work
pAcpA	pKK214 with <i>acpA</i> for complementation study	This work

(CHA) (Hi-Media Laboratories, India) and in modified tryptic soy broth (Difco Laboratories, Detroit, MI) containing 135  $\mu$ g/ml ferric pyrophosphate and 0.1% cysteine hydrochloride. CHA containing 5% defibrinated sheep blood and 135  $\mu$ g/ml ferric pyrophosphate was used for transformation studies (Hemostat Laboratories, Dixon, CA). When required, the growth medium for wild-type (WT) *F. novicida* was supplemented with kanamycin (25  $\mu$ g/ml) or tetracycline (12.5  $\mu$ g/ml). All manipulations with *Francisella* spp. were performed in a class II biological safety laboratory. *E. coli* DH5 $\alpha$  was grown at 37°C aerobically in Luria-Bertani (LB) medium (Difco Laboratories, Detroit, MI) supplemented with kanamycin (15  $\mu$ g/ml), tetracycline (12.5  $\mu$ g/ml), or ampicillin (100  $\mu$ g/ml) when required. All antibiotics and chemicals were purchased from Sigma-Aldrich (St. Louis, MO).

Chromosomal DNA preparation, ligation, *E. coli* transformation, and Southern blotting were performed according to methods described previously by Sambrook et al. (32). To construct plasmid pAcpA-Kan, upstream and downstream regions of *acpA* were generated by PCR with primer pairs JG996/JG997 and JG998/JG999, respectively, from WT genomic DNA. The 772-bp upstream fragment was digested with SacI and KpnI, cloned into dephosphorylated SacI- and KpnI-digested pUC18, and renamed pAcpUp. Similarly, the 871-bp downstream region of *acpA* was digested with PstI and SphI, cloned into dephosphorylated PstI- and SphI-digested plasmid pAcpUp, and renamed pAcpUpDn. A kanamycin (Kan) cassette driven by the *F. tularensis* outer membrane protein (GenBank accession number YP\_169847) promoter was amplified from plasmid pDSK519 using primer pair JG868/JG1048, digested with KpnI and PstI, ligated into the KpnI/PstI-digested and dephosphorylated pAcpUpDn vector, and renamed pAcpA-Kan. Plasmid pAcpA-Kan was transformed into WT cells by cryotransformation. In brief, 1  $\mu$ g of plasmid was mixed with WT cells (optical density at 600 nm of 0.5) in transformation buffer (10 mM MOPS [morpholinepropanesulfonic acid], 75 mM CaCl<sub>2</sub>, 10 mM RbCl<sub>2</sub>, and 15% glycerol, with the pH adjusted to 6.5 with 1 N KOH), incubated on ice for 30 min, and flash frozen in liquid nitrogen for 5 min. Cells were thawed at room temperature, plated onto CHA-Kan, and incubated at 37°C. This resulted in the creation of strain JSG2660 ( $\Delta acpA::kan$ ). Growth curves were identical for strain JSG2660 and the WT. For complementation in *trans*, plasmid pKK214 containing the *groEL* promoter of *F. tularensis* LVS was used (1). The *acpA* gene was generated by PCR using primer pair JG1016a/JG1017a and cloned into the EcoRI and PstI sites of pKK214groEL such that *acpA* was expressed from the *groEL* promoter. The resulting plasmid, pAcpA, was introduced into JSG2660 by cryotransformation as described above, creating strain JSG2661.

For Southern blot analysis, PCR products were labeled with digoxigenin according to instructions provided by the manufacturer (Roche, Indianapolis, IN). Probes were hybridized to EcoRI-digested chromosomal DNA of WT *F. novicida* and the *F. novicida*  $\Delta acpA$  strain followed by anti-digoxigenin-alkaline phos-

TABLE 2. Oligonucleotide primers

Primer	Sequence (5'-3')
JG996.....	CGAGCTCCATCACCTTCTTCATAATGAGAGAA TTTCTTAAGCGCATGACC
JG997.....	GGGGTACCATGATACCTTTAGTTGTTAGATTCC AAAGGAAATATTAATAAC
JG998.....	AACTGCAGCTCGGTAAGTTGCTTTAATCTAGT ATTTTCGCTTATTGCCTCTTCTAAACTTAC
JG999.....	ACATGCATGCCATTTCAGATAGTAGTATAGCCT TAGAGTTAGCAAGAGTTGTATAAAAAATA AAGGTTAAGC
JG868.....	CGGAATTCGGATCCCTGCAGATCGATTGTTGT TTCAAGTTTTGATAATGATTAATAATAATA GGAGTTAAAAATGAGCCATATTCAACGGGA AACG
JG1048.....	AACTGCAGTTAGAAAACTCATCGAGCATCA AATGAAACTGC
JG1016a.....	AACTGCAGGCATGCAGAGGAGGTTTTTAA TGAAGCTCAATAAAAAATTACTTTAGGAATTTT AAGTCTAAGTATCGC
JG1017a.....	CGGAATTCCTTAGTTTAAATTTATCCACTACTAA TCCTGTCTTAGGGTCTAAAATC

phatase conjugate antibody treatment. Membranes were developed with nitroblue tetrazolium/BCIP (5-bromo-4-chloro-3-indolylphosphate) solution.

**Cell fractionation.** Stationary-phase cultures of wild-type (JSG1819) and mutant (JSG2660) bacteria grown overnight in tryptic soy broth-0.1% cysteine hydrochloride were centrifuged at 8,000  $\times$  g for 20 min at 4°C. The cell pellet was washed twice with phosphate-buffered saline (PBS) and sonicated at a constant output of 60 W for a total of 300 s. Cell debris and unbroken cells were removed by centrifugation at 3,000  $\times$  g for 15 min at 4°C. The supernatant was centrifuged at 100,000  $\times$  g for 24 h at 18°C in a gradient of 2.1 to 1.4 to 0.7 M sucrose to separate the outer and inner membrane fractions. The non-membrane-containing fraction was used as the cytosolic fraction. These fractions were assayed for phosphatase activity as described previously by Aragon et al. (3) Western blot analysis was performed on protein fractions using anti-AcpA polyclonal sera (gift of Tom Reilly) by standard protocols.

**Intramacrophage survival assays.** The WT or the  $\Delta acpA$  strain was used to infect J774.1 murine macrophages, NR8383 rat alveolar macrophages, and phorbol myristate acetate-induced (10 ng/ml) THP-1 human macrophages at a multiplicity of infection (MOI) of ~50:1. Wells were seeded with  $\sim 2 \times 10^5$  macrophages, and  $\sim 1.0 \times 10^7$  bacteria were added to each well. After 2 h of incubation at 37°C and 5% CO<sub>2</sub>, gentamicin (50  $\mu$ g/ml) was added to the medium to eliminate extracellular organisms. Wells were washed twice with PBS and incubated with their respective media supplemented with 10  $\mu$ g/ml gentamicin. The macrophage cells were lysed with 0.1% sodium dodecyl sulfate at 2 h, 12 h, and 24 h postinfection, and the lysates were immediately serially diluted in PBS and plated onto CHA plates for determination of viable counts. Experiments were performed in triplicate on a minimum of three separate occasions with similar results.

**Transmission electron microscopy.** Monolayers of monocyte-derived macrophages (MDMs) (24) or THP-1 cell lines were incubated with the WT (JSG1819) or the  $\Delta acpA$  strain (JSG2660) at an MOI of 500:1 in a plastic four-well chamber slide. This high MOI was used to enhance the number of macrophages in the population that were infected, which in turn aided visualization. After 2, 6, and 12 h of incubation at 37°C and 5% CO<sub>2</sub>, the wells were washed and fixed immediately with 2.5% warmed glutaraldehyde for 5 min followed by a combination of 2.5% glutaraldehyde and 1% osmium tetroxide in 0.1 M sodium cacodylate, pH 7.3, for 15 min at 4°C (11). The cells were then stained with 0.25% uranyl acetate in 0.1 M sodium acetate buffer at pH 6.3 for 45 min. Monolayers were washed with ice-cold normal saline, and the chambers were then removed. Slides were dehydrated through a graded series of ethanol, rinsed in hydroxypropylmethylacrylate, and infiltrated with Polybed 812. They were embedded by up-ending resin-filled beam capsules over the cells and polymerized at 60°C for 24 h. Thin sections cut with a Leica EM UC6 ultramicrotome were collected onto Formvar-coated copper grids, stained with uranyl acetate and lead citrate, and viewed by transmission electron microscopy using a Philips CM12 transmission electron microscope at 60 kV. Multiple fields were examined for bacteria, and identified bacteria were determined to be intraphagosomal or intracytosolic. The




FIG. 1. Construction and confirmation of the  $\Delta acpA$  mutant. (A) Southern blot analysis of the chromosomal DNA of the  $\Delta acpA$  mutant versus the WT. DNAs were digested with EcoRI and probed with the *acpA* ORF (lanes 1 and 2) or the *kan* cassette (lanes 3 and 4) showing the expected differential hybridization of the probe. An EcoRI site within the *acpA* ORF results in two hybridizing bands, while no EcoRI sites were found within the *acpA* ORF. Lanes 1 and 3, *F. novicida*; lanes 2 and 4, *F. novicida*  $\Delta acpA$ . (B) Western blot analysis of whole-cell lysates (WC), outer membrane fractions (OM), and inner membrane fractions (IM) of the WT, the  $\Delta acpA$  strain, and Schu 4 detecting the 57-kDa AcpA protein. Rabbit polyclonal anti-AcpA serum was used as the primary antibody.

criterion for intraphagosomal bacteria was the visualization of more than 50% of the phagosomal membrane surrounding the bacterium.

**Mouse survival studies.** Groups of five female 4- to 6-week-old BALB/c mice (Harlan Sprague) were inoculated at a dose of  $\sim 100$  CFU delivered in 100  $\mu$ l PBS by the intraperitoneal route. Actual bacterial counts delivered were determined by plate count from each inoculum. Mice were monitored for 4 days postinfection. For competition assays, wild-type (JSG1819) and mutant (JSG2660) bacteria were inoculated into BALB/c mice at a 1:1 ratio (100 CFU of each in 100  $\mu$ l total), and at 4 days postinoculation, organs were harvested, macerated, and plated onto appropriate solid media to select for each of the competing strains. The competitive index was calculated as the number of mutant CFU/WT CFU recovered.

## RESULTS

**Construction of a  $\Delta acpA$  mutant.** A modified cryotransformation technique that increased the efficiency of transformation 100- to 1,000-fold in comparison to the standard *Francisella*  $MgCl_2$ -KCl cryotransformation or electroporation was developed. This technique was used to introduce pAcpA-Kan, a nonreplicating suicide vector carrying a DNA fragment with a kanamycin cassette in the place of a complete deletion of *acpA*, into WT cells. After 5 days of growth on CHA-Kan plates, several colonies were screened by PCR and Southern blotting, resulting in the identification of more than 85% of the clones with the correct deletion and loss of the vector sequences (Fig. 1A).

**Comparative measurements of acid phosphatase and lipase activity.** WT and  $\Delta acpA$  cells were disrupted and separated by a sucrose gradient to recover inner and outer membrane fractions. A Western blot analysis was performed, which showed the presence of AcpA in whole-cell lysates and the outer membrane fraction of WT cells (Fig. 1B). AcpA was absent in all fractions analyzed from the  $\Delta acpA$  strain. A single band of similar molecular weight was detected in a Schu 4 whole-cell lysate, demonstrating its expression in type A virulent *Francisella*. Acid phosphatase activities of the *F. novicida* cell ex-




FIG. 2. Acid phosphatase (A) and lipase (B) activities of inner membrane (IM), outer membrane (OM), and cytoplasmic (Cyt) fractions of the  $\Delta acpA$  (gray bars) versus the  $\Delta acpA$  complemented (white bars) and parental (black bars) strains. Data represent the means  $\pm$  standard deviations of three independent experiments each with duplicate wells.

tracts and inner and outer membrane fractions were measured. Using 6,8-difluoro-4-methylumbelliferyl phosphate as the substrate, we found no difference in the phosphatase activities of cell extracts/cytosolic fractions or inner membrane fractions between the mutant and wild-type strains but a 10-fold decrease in phosphatase activity of the mutant outer membrane fraction (Fig. 2A). This was consistent with the observed location of the enzyme in the outer membrane fraction (Fig. 1B). Complementation of the  $\Delta acpA$  strain with a plasmid containing the *acpA* gene restored outer membrane phosphatase activity to the wild-type level (Fig. 2A). Using *p*-nitrophenyl palmitate as the substrate, we also measured an eightfold decrease in phospholipase activity recovered from the outer membrane fraction of the  $\Delta acpA$  strain compared to the WT (Fig. 2B). These results are consistent with the predicted secretion of AcpA into the periplasmic space and suggest a tight association with the outer membrane. In addition, these data demonstrate that the  $\Delta acpA$  strain has significantly reduced enzymatic activities that are associated with AcpA.

**The  $\Delta acpA$  strain is defective in intramacrophage survival/replication.** The primary cellular target of *F. tularensis* during infection is the macrophage (26, 39). To examine the role that AcpA may play in protecting *Francisella* from phagocytic killing and intracellular trafficking, we measured the survival of the  $\Delta acpA$  strain in the THP-1 cell line. While the WT and the  $\Delta acpA$  complemented strains replicated within the THP-1 cells, the  $\Delta acpA$  strain showed about a half-log reduction over 12 h postinfection, with a slight recovery to the initial infection numbers by 24 h (Fig. 3). The experiment was not continued




FIG. 3. Intramacrophage survival assays performed in THP-1 human macrophage-like cell lines with the *ΔacpA* (squares), *ΔacpA* complemented (triangles), and parental (diamonds) strains. Data represent means  $\pm$  standard deviations of three independent experiments each with duplicate wells for each time point. Asterisks denote significant differences for the *ΔacpA* mutant compared to the WT at 12 and 24 h postinfection ( $P < 0.005$ , Student's *t* test).

beyond 24 h due to a loss of macrophage viability. Similar results were observed in murine and rat macrophage cell lines (data not shown). These results demonstrate that AcpA plays a role in the intramacrophage survival and/or replication of WT *F. novicida*.

**Electron microscopy demonstrates delayed phagosomal escape of the *acpA* mutant.** To further delineate the function of AcpA in intramacrophage survival, we used transmission electron microscopy to visualize phorbol myristate acetate-stimulated THP-1 cells and MDMs infected with either the WT or the *ΔacpA* strain (Fig. 4 and 5). At 2 h postinfection in both macrophages, nearly all of the mutant and wild-type bacteria were contained in membrane-bound vacuoles, consistent with the known early compartmentalization of the pathogen in phagosomes (Fig. 4A and 5A). After 6 h, over half of WT cells had escaped from phagosomes (Fig. 4B and 5B), and by 12 h postinfection, almost none of the wild-type pathogen was contained inside vacuoles with distinct membrane boundaries in THP-1 cells (Fig. 4C). Studies with MDMs revealed similar findings, except that the escape of WT cells at 12 h was slower, such that 40% of the cells were still in intact membranes (versus 75% of the *ΔacpA* cells) (Fig. 5C). In sharp contrast, we observed very little degradation of vacuoles containing *ΔacpA* cells during the 12-h timeframe of the experiments. After 12 h, approximately 75% of *ΔacpA* cells were still contained in vacuoles with distinct membrane borders (Fig. 4D and 5D). These results suggest that AcpA plays a role in intramacrophage survival/replication via the disruption of the phagosomal membrane that allows *Francisella* cells access to the host cell cytosol.

**The *ΔacpA* mutant has reduced virulence in the mouse model.** To examine the role of AcpA in an animal model of infection, we measured survival rates of mice infected with WT and *ΔacpA* cells. After 36 h following intraperitoneal infection, only 20% of the mice infected with the WT had survived, while 80% of the mice infected with the *ΔacpA* strain survived (Fig. 6). At the 48-h time point, all mice infected with the WT were dead, while 60% of those infected with the *ΔacpA* strain survived. However, by 72 h postinfection, all mice had died. Competition assays corroborated the apparent decrease in *ΔacpA* strain virulence, demonstrating a consistent competitive index




FIG. 4. Transmission electron microscopy images of THP-1 cells infected with the *acpA* null strain of *F. novicida* (left panel) and the WT (right panel) obtained 2 h (A), 6 h (B), and 12 h (C) postinfection and (D) semiquantitative assessment of bacteria within/outside of phagosomes as determined by counting phagosomes in a minimum of 100 cross-sections/test group. Gray bars, *ΔacpA*; black bars, parental strain. The width of each panel in A, B, and C is 2.87  $\mu$ m.

of  $\sim 0.17$  in both liver and spleen. These data indicate that the loss of AcpA activity results in a less virulent pathogen, which is presumably due to decreased intramacrophage survival. Because mice infected with the *ΔacpA* strain eventually died, it is likely that AcpA acts in concert with other factors to disrupt normal intracellular trafficking and that the influence of AcpA is greatest in the initial stages of infection.

## DISCUSSION

*Francisella* AcpA possesses physical and chemical properties unlike other bacterial acid phosphatases (20, 31). This 57-kDa enzyme hydrolyzes a wide variety of physiologically meaningful substrates, including phosphorylated tyrosine peptides, inositol phosphates, phospholipid-like molecules, AMP, ATP, fructose-1,6-bisphosphate, glucose- and fructose-6-phosphates, NADP, and ribose-5-phosphate, but fails to possess significant similarity to other acid phosphatases in the protein database (27, 28). It has recently been crystallized (14), and the




FIG. 5. Transmission electron microscopy images of MDM cells infected with the *acpA* null strain of *F. novicida* (left panel) and WT *F. novicida* (right panel) obtained 2 h (A), 6 h (B), and 12 h (C) postinfection and (D) semiquantitative assessment of bacteria within/outside of phagosomes in a minimum of 100 cross-sections/test group. Gray bars,  $\Delta acpA$ ; black bars, parental strain. The width of each panel in A, B, and C is 1.5  $\mu\text{m}$ .

completed structure of this enzyme will likely provide important clues to its biological functions.

Many acid phosphatases have been shown or predicted to play a role in virulence, most often in intracellular pathogens, by the inhibition of a respiratory burst. Such activity has been reported for AcpA of the WT (27) as well as for *Coxiella burnetii* (4), *Legionella* spp. (31), and *Leishmania* (29). In this study, we described the role of *Francisella* AcpA, which has dual acid phosphatase and phospholipase C activities, in virulence and phagosomal trafficking in macrophages.

In this work, we constructed a complete deletion of the *acpA* open reading frame (ORF). A previous study of AcpA in the WT concluded that upon the chromosomal deletion of a 300-bp 3' region and the replacement of this region by an erythromycin cassette, there was no effect upon intramacrophage survival or virulence (7). We were therefore somewhat surprised by the phenotypes observed due to the complete deletion of *acpA*. It is possible that since the entire *acpA* ORF was not deleted in the previous study, a functional truncated




FIG. 6. Survival of BALB/c mice following intraperitoneal infection with the *F. novicida*  $\Delta acpA$  strain (squares), the  $\Delta acpA$  complemented strain (triangles), and the parental strain (diamonds). A total of 10 mice/strain were used in two independent experiments. Asterisks denote significant differences for the  $\Delta acpA$  mutant versus the WT at 36 and 48 h postinfection ( $P < 0.005$ , Student's *t* test).

protein was still produced. With regard to acid phosphatase activity, this may be unlikely, as the peak of phosphatase activity in protein fractions associated with AcpA was absent in the previously described mutant. However, it is possible that the truncated protein retained phospholipase activity, and it is this activity that is important for phagosomal trafficking.

It was shown that the phosphatase and phospholipase activities of the  $\Delta acpA$  mutant had 10-fold and 8-fold less activity than the WT, respectively, indicating that AcpA contributed to the overall activity but that it is not the only phosphatase or phospholipase in the WT. Indeed, enzyme assays have shown at least two peaks of phosphatase activity in crude protein fractions (7), and genome scanning shows three other acid phosphatases in the WT (unpublished observations). The future characterization and mutagenesis of these additional acid phosphatases will help to define the individual contributions of each enzyme to the biology of *Francisella*.

We determined the growth kinetics of the *acpA* mutant and compared them to those of the WT in various macrophage cell lines, where we showed that the *acpA* mutant exhibited a 10- to 20-fold reduction in survival in THP-1 cells. This phenotype was due to the loss of *acpA*, as the complemented mutant strain revealed intramacrophage growth kinetics identical to those of the WT strain. To explore the survival or growth of the *acpA* mutant in vivo, mice were infected intraperitoneally (and intranasally, with similar results) (data not shown). We found that mice infected with the *acpA* mutant survived longer than mice infected with the WT strain, and there was a corresponding reduction in organ bacterial load. When mice were infected with a mixture of WT and *acpA* mutant strains at a ratio of 1:1, the *acpA* mutant strain was less competitive than the WT strain (competitive index of  $\sim 0.17$  in both liver and spleen). These data suggest that AcpA contributes to virulence. It is possible that a greater virulence defect will be observed upon the deletion of multiple acid phosphatase genes.

It has been shown that *Francisella* spp. are initially contained within a phagosome but later escape into cytoplasm (11, 33, 34). The factors involved in and the mechanism of phagosomal escape are largely unknown, but IglC and MglA have been shown to play a role (33). We found that in THP-1 cells and MDMs, the  $\Delta acpA$  mutant was still located primarily inside the phagosome at 6 h postinfection and only poorly escaped into

the cytoplasm after 12 h of infection, whereas the WT was nearly 100% and 60% escaped from phagosomes by 12 h of infection in THP-1s and MDMs, respectively. These data suggest that AcpA plays a role in intramacrophage trafficking, and the inability of the mutant to escape from the phagosome likely contributes to its decreased intramacrophage survival and virulence.

Because AcpA has numerous enzymatic targets, a challenge for the future is to determine which of these enzymatic activities underlies the observed respiratory burst suppression and altered phagosomal escape due to AcpA. One possibility is that AcpA hydrolyzes phospholipids of the phagosomal inner membrane, which might compromise membrane integrity. Alternatively, AcpA might affect host signaling pathways by dephosphorylation of host proteins, inositol phosphates or phosphoinositides, with the latter being critically important for phagosome formation (37) and respiratory burst activation (5). A third hypothesis is that AcpA activity within the bacterium helps to induce or amplify the activity of other proteins that are essential for phagosome disruption, such as IglC and its regulator, MglA (22, 33). In this context, the polyspecificity and high abundance of AcpA may point to a phosphate scavenger role for the enzyme (41). Based on structural, enzymatic, and phenotypic properties, inhibitors of AcpA and other acid phosphatases may be developed that, when used in combination with other antimicrobial agents, would provide alternative therapy against *F. tularensis* infection.

#### ACKNOWLEDGMENTS

This work was supported by National Institutes of Health grants U56AI057164 (Midwest Center of Excellence [MWCE] Transmission/Pathogenesis of Bioterrorism Agents to L.S.S.), U54AI057153 (Region V "Great Lakes" Regional Center of Excellence in Biodefense and Emerging Infectious Diseases Consortium [GLRCE] to L.S.S. and J.S.G.), and U54AI057156 (Western Regional Center of Excellence for Biodefense and Emerging Infectious Diseases to J.S.G.) and an NIH institutional training grant, AI 0155411 (to A.B.).

We thank Karen Elkins and Fran Nano for providing guidance and *Francisella* strains and Jack Tanner and Tom Reilly for their advice and critical reading of the manuscript.

#### REFERENCES

1. Abd, H., T. Johansson, I. Golovliov, G. Sandström, and M. Forsman. 2003. Survival and growth of *Francisella tularensis* in *Acanthamoeba castellanii*. *Appl. Environ. Microbiol.* **69**:600–606.
2. Anthony, L. D., R. D. Burke, and F. E. Nano. 1991. Growth of *Francisella* spp. in rodent macrophages. *Infect. Immun.* **59**:3291–3296.
3. Aragon, V., S. Kurtz, A. Flieger, B. Neumeister, and N. P. Cianciotto. 2000. Secreted enzymatic activities of wild-type and *pilD*-deficient *Legionella pneumophila*. *Infect. Immun.* **68**:1855–1863.
4. Baca, O. G., M. J. Roman, R. H. Glew, R. F. Christner, J. E. Buhler, and A. S. Aragon. 1993. Acid phosphatase activity in *Coxiella burnetii*: a possible virulence factor. *Infect. Immun.* **61**:4232–4239.
5. Baggiolini, M., and M. P. Wymann. 1990. Turning on the respiratory burst. *Trends Biochem. Sci.* **15**:69–72.
6. Baron, G. S., and F. E. Nano. 1998. MglA and MglB are required for the intramacrophage growth of *Francisella novicida*. *Mol. Microbiol.* **29**:247–259.
7. Baron, G. S., T. J. Reilly, and F. E. Nano. 1999. The respiratory burst-inhibiting acid phosphatase AcpA is not essential for the intramacrophage growth or virulence of *Francisella novicida*. *FEMS Microbiol. Lett.* **176**:85–90.
8. Berman, H. M., J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissig, I. N. Shindyalov, and P. E. Bourne. 2001. The Protein Data Bank. *Nucleic Acids Res.* **28**:235–242.
9. Chen, W., H. Shen, A. Webb, R. KuoLee, and J. W. Conlan. 2003. Tularemia in BALB/c and C57BL/6 mice vaccinated with *Francisella tularensis* LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background. *Vaccine* **21**:3690–3700.
10. Chu, M. C., and R. Weyant. 2003. *Francisella* and *Brucella*, p. 789–797. In P. R. Murray, E. J. Baron, J. H. Tenover, M. A. Tenover, and R. H. Tenover (ed.), *Manual of clinical microbiology*, 8th ed. ASM Press, Washington, DC.
11. Clemens, D. L., B. Y. Lee, and M. A. Horvitz. 2004. Virulent and avirulent strains of *Francisella tularensis* prevent acidification and maturation of their phagosomes and escape into the cytoplasm in human macrophages. *Infect. Immun.* **72**:3204–3217.
12. Eigelsbach, H. T., and C. M. Downs. 1961. Prophylactic effectiveness of live and killed tularemia vaccines. I. Production of vaccine and evaluation in the white mouse and guinea pig. *J. Immunol.* **87**:415–425.
13. Eigelsbach, H. T., J. Tulis, E. L. Overholt, and W. R. Griffith. 1961. Aerogenic immunization of the monkey and guinea pig with live tularemia vaccine. *Proc. Soc. Exp. Biol. Med.* **108**:732–734.
14. Felts, R. L., T. J. Reilly, and J. J. Tanner. 2005. Crystallization of AcpA, a respiratory burst-inhibiting acid phosphatase from *Francisella tularensis*. *Biochim. Biophys. Acta* **1752**:107–110.
15. Golovliov, I., V. Baranov, Z. Krocova, H. Kovarova, and A. Sjøstedt. 2003. An attenuated strain of the facultative intracellular bacterium *Francisella tularensis* can escape the phagosome of monocytic cells. *Infect. Immun.* **71**:5940–5950.
16. Golovliov, I., A. Sjøstedt, A. Mokrievich, and V. A. Pavlov. 2003. Method for allelic replacement in *Francisella tularensis*. *FEMS Microbiol. Lett.* **222**:273–280.
17. Gray, C. G., S. C. Cowley, K. K. Cheung, and F. E. Nano. 2002. The identification of five genetic loci of *Francisella novicida* associated with intracellular growth. *FEMS Microbiol. Lett.* **215**:53–56.
18. Hodge, F. A., W. R. Leif, and M. S. Silverman. 1968. Susceptibility to infection with *Pasteurella tularensis* and the immune response of mice exposed to continuous low dose rate gamma radiation. *Natl. Radiol. Defense Lab. Trans.* **68**:1–28.
19. Kieffer, T., S. Cowley, F. E. Nano, and K. L. Elkins. 2003. *Francisella novicida* LPS has greater immunobiological activity in mice than *F. tularensis* LPS, and contributes to *F. novicida* murine pathogenesis. *Microbes Infect.* **5**:397–403.
20. Kondo, E., T. Kurata, P. Naigowit, and K. Kanai. 1996. Evolution of cell-surface acid phosphatase of *Burkholderia pseudomallei*. *Southeast Asian J. Trop. Med. Public Health* **27**:592–599.
21. Larsson, P., P. C. F. Oyston, P. Chain, M. C. Chu, M. Duffield, H. H. Fuxelius, E. Garcia, G. Hålltorp, D. Johansson, K. E. Isherwood, P. D. Karp, E. Larsson, Y. Liu, S. Michell, J. Prior, R. Prior, S. Malfatti, A. Sjøstedt, K. Svensson, N. Thompson, L. Vergez, J. K. Wagg, B. W. Wren, L. E. Lindler, S. G. E. Andersson, M. Forsman, and R. W. Titball. 2005. The complete genome sequence of *Francisella tularensis*, the causative agent of tularemia. *Nat. Genet.* **37**:153–159.
22. Lauriano, C. M., J. R. Barker, S. S. Yoon, F. E. Nano, B. P. Arulanandam, D. J. Hassett, and K. E. Klose. 2004. MglA regulates transcription of virulence factors necessary for *Francisella tularensis* intra-macrophage and intramacrophage survival. *Proc. Natl. Acad. Sci. USA* **101**:4246–4249.
23. Markova, N., V. Kussovski, and T. Radoucheva. 1998. Killing of *Pseudomonas pseudomallei* by polymorphonuclear leukocytes and peritoneal macrophages from chicken, sheep, swine and rabbits. *Zentralbl. Bakteriol.* **288**:103–110.
24. McCarthy, T. R., J. B. Torrelles, A. S. MacFarlane, M. Katakczik, B. Kutzbach, L. E. DesJardin, S. Clegg, J. B. Goldberg, and L. S. Schlesinger. 2005. Overexpression of *Mycobacterium tuberculosis manB*, a phosphomannomutase that increases phosphatidylinositol mannoside biosynthesis in *Mycobacterium smegmatis* and mycobacterial association with human macrophages. *Mol. Microbiol.* **58**:774–790.
25. Nano, F. E., N. Zhang, S. C. Cowley, K. E. Klose, K. K. M. Cheung, M. J. Roberts, J. S. Ludu, G. W. Letendre, A. I. Meierovics, G. Stephens, and K. L. Elkins. 2004. A *Francisella tularensis* pathogenicity island required for intramacrophage growth. *J. Bacteriol.* **186**:6430–6436.
26. Oyston, P. C., A. Sjøstedt, and R. W. Titball. 2004. Tularemia: bioterrorism defence renews interest in *Francisella tularensis*. *Nat. Rev. Microbiol.* **2**:967–978.
27. Reilly, T. J., G. S. Baron, F. E. Nano, and M. S. Kuhlenschmidt. 1996. Characterization and sequencing of a respiratory burst-inhibiting acid phosphatase from *Francisella tularensis*. *J. Biol. Chem.* **271**:10973–10983.
28. Reilly, T. J., R. L. Felts, M. T. Henzl, M. J. Calcutt, and J. J. Tanner. 2006. Characterization of recombinant *Francisella tularensis* acid phosphatase A. *Protein Expr. Purif.* **45**:132–141.
29. Remaley, A. T., R. H. Glew, D. B. Kuhns, R. E. Basford, A. S. Waggoner, L. A. Ernst, and M. Pope. 1985. *Leishmania donovani*: surface membrane acid phosphatase blocks neutrophil oxidative metabolite production. *Exp. Parasitol.* **60**:331–341.
30. Rossolini, G. M., S. Schippa, M. L. Riccio, F. Berlutti, L. E. Macaskie, and M. C. Thaller. 1998. Bacterial nonspecific acid phosphohydrolases: physiology, evolution and use as tools in microbial biotechnology. *Cell. Mol. Life Sci.* **54**:833–850.
31. Saha, A. K., J. N. Dowling, K. L. LaMarco, S. Das, A. T. Remaley, N. Olomu, M. T. Pope, and R. H. Glew. 1985. Properties of an acid phosphatase from *Legionella micdadei* which blocks superoxide anion production by human neutrophils. *Arch. Biochem. Biophys.* **243**:150–160.

32. **Sambrook, J., E. F. Fritsch, and T. Maniatis.** 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
33. **Santic, M., M. Molmeret, and Y. Abu Kwaik.** 2005. Modulation of biogenesis of the *Francisella tularensis* subsp. *novicida*-containing phagosome in quiescent human macrophages and its maturation into a phagolysosome upon activation by IFN-gamma. *Cell. Microbiol.* **7**:957–967.
34. **Santic, M., M. Molmeret, K. E. Klose, S. Jones, and Y. A. Kwaik.** 2005. The *Francisella tularensis* pathogenicity island protein IglC and its regulator MglA are essential for modulating phagosome biogenesis and subsequent bacterial escape into the cytoplasm. *Cell. Microbiol.* **7**:969–979.
35. **Saslaw, S., H. T. Eigelsbach, H. E. Wilson, J. A. Prior, and S. Carhart.** 1961. Tularemia vaccine study. I. Intracutaneous challenge. *Arch. Int. Med.* **107**: 689–701.
36. **Shen, H., W. Chen, and J. W. Conlan.** 2004. Susceptibility of various mouse strains to systemically- or aerosol-initiated tularemia by virulent type A *Francisella tularensis* before and after immunization with the attenuated live vaccine strain of the pathogen. *Vaccine* **22**:2116–2121.
37. **Simonsen, A., A. E. Wurmser, S. D. Emr, and H. Stenmark.** 2001. The role of phosphoinositides in membrane transport. *Curr. Opin. Cell Biol.* **13**:485–492.
38. **Tärnvik, A.** 1989. Nature of protective immunity to *Francisella tularensis*. *Rev. Infect. Dis.* **11**:440–451.
39. **Titball, R. W., A. Johansson, and M. Forsman.** 2003. Will the enigma of *Francisella tularensis* virulence soon be solved? *Trends Microbiol.* **11**:118–123.
40. **Williams, M. D., T. X. Ouyang, and M. C. Flickinger.** 1994. Glutathione S-transferase-sspA fusion binds to *E. coli* RNA polymerase and complements delta *sspA* mutation allowing phage P1 replication. *Biochem. Biophys. Res. Commun.* **201**:123–127.
41. **Yang, K., and W. W. Metcalf.** 2004. A new activity for an old enzyme: *Escherichia coli* bacterial alkaline phosphatase is a phosphite-dependent hydrogenase. *Proc. Natl. Acad. Sci. USA* **101**:7919–7924.

---

Editor: V. J. DiRita